Stellate ganglion block, or SGB, involves injecting a local anesthetic near the stellate ganglion, a cluster of sympathetic nerve cells located in the neck. The goal is to modulate autonomic nervous system activity, and the technique has a long history in pain management and certain circulatory disorders. More recently, it has been investigated as an option for patients with stubborn insomnia who have not responded to conventional treatments. The appeal is understandable: the procedure is minimally invasive, can be performed on an outpatient basis, and some studies suggest it may improve sleep quality and overall well-being in selected patients. But as this case demonstrates, the neck is a crowded anatomical neighborhood, and needles placed near the sympathetic chain sit close to structures that the body cannot easily spare.

The patient in question had endured six months of severe insomnia before arriving at the clinic. She was sleeping roughly four hours a night, taking about ninety minutes to fall asleep, and waking four to five times nightly. Standardized questionnaires confirmed moderate-to-severe chronic insomnia: her Pittsburgh Sleep Quality Index score was 16 and her Insomnia Severity Index score was 21. She had already tried sleep hygiene education, the sedative estazolam, and melatonin with limited benefit. Her medical history included well-controlled hypertension but no cervical spine disease, trauma, or neurological disorders. Neurological examination and cervical MRI before the procedure were normal, and she showed no clinical features suggesting sleep apnea or other sleep-related movement disorders. With conservative options exhausted, her care team proceeded with a right-sided stellate ganglion block.

The procedure itself followed the modern playbook. An experienced anesthesiologist used a high-frequency linear ultrasound transducer to visualize the anatomy at the level of the sixth cervical vertebra, identifying the carotid artery, internal jugular vein, thyroid gland, and the longus colli muscle before advancing a 22-gauge needle from the side in real time. Color Doppler imaging confirmed that no vessels lay along the planned trajectory. After negative aspiration for blood and cerebrospinal fluid, the physician slowly injected 3 milliliters of 0.2 percent ropivacaine combined with 1 milliliter of compound betamethasone, a corticosteroid added to prolong the block’s effect and dampen local inflammation. Throughout needle advancement and injection, the patient reported no radiating pain, tingling, or weakness — and the injection was completed as planned.

Then, roughly one minute after the needle was withdrawn, everything changed. The patient suddenly reported severe, electric shock-like pain radiating from her right shoulder down the lateral aspect of her upper arm, followed by weakness in shoulder abduction and elbow flexion. Because the symptoms appeared only after the injection had finished, there had been no opportunity to halt the procedure in response to warning signs. Two hours later, examination revealed Medical Research Council grade 3 out of 5 strength in the right deltoid and biceps muscles, reduced pinprick sensation over the lateral upper arm in the C5 dermatome, and a diminished biceps tendon reflex. Emergency cervical MRI ruled out disc herniation, hematoma, or any other compressive lesion that could explain the sudden deficit.

Three days after the procedure, with symptoms persisting well beyond the expected duration of the local anesthetic, electromyography was performed. The results showed abundant spontaneous electrical activity — fibrillation potentials and positive sharp waves — along with markedly reduced recruitment in the deltoid and biceps, muscles predominantly supplied by the C5 nerve root. Critically, sensory nerve action potentials were preserved, a pattern that points toward a preganglionic nerve root lesion rather than an injury to a distal peripheral nerve. The authors were careful to note, however, that the clinical picture of deltoid and biceps weakness also overlaps with partial involvement of the upper trunk of the brachial plexus, and because the patient declined dedicated brachial plexus MRI and no repeat electromyography was available, definitive anatomical localization remained out of reach. The findings were therefore interpreted as favoring C5-predominant involvement rather than proving an isolated root injury.

The mechanism of injury remains uncertain, and the authors are candid about that limitation. Real-time ultrasound never provided unequivocal evidence of an intraneural or intrafascicular injection, and the stored images, being static snapshots, could not confirm that the needle had penetrated a specific neural structure. Inadvertent needle-to-nerve contact, unintended perineural or limited intraneural spread, and injection-related neural irritation all remained plausible explanations. Previous MRI research has shown that even small-volume injectate can distribute across vertebral levels from roughly C5 to T1, lending anatomical plausibility to the idea that the solution reached nerve root territory, though the authors stress this evidence supports only possibility, not proof of what happened in this patient. The role of the betamethasone additive is likewise unclear; its use was extrapolated from other regional anesthesia settings, and direct evidence for corticosteroid adjuncts in SGB for insomnia remains thin.

The recovery trajectory offers a measure of reassurance. Treatment with neurotrophic support — mecobalamin and vitamin B1 — combined with physical therapy, including ultrashort-wave therapy and medium-frequency electrical stimulation, began promptly. Pain on a 10-point visual analogue scale fell from 8 at onset to 3 at two weeks and 1 at three months. Muscle strength in the deltoid and biceps improved from grade 3 to grade 4+ out of 5 by the three-month follow-up, sensory abnormalities had largely resolved, and, somewhat remarkably, the patient’s insomnia symptoms had also improved. Still, the absence of repeat electromyography and validated functional outcome measures means the full extent of electrophysiological recovery could not be objectively characterized.

What makes this case resonate beyond a single patient is the broader context. C5 and C6 nerve root injuries have been described after cervical spine surgery and nerve root injections, but C5-predominant neurological injury following SGB performed for a sleep disorder has rarely, if ever, been documented. As SGB attracts growing interest for psychiatric and sleep-related indications — including post-traumatic stress disorder and menopausal insomnia — the population of patients exposed to the procedure is expanding well beyond the pain clinics where it was first refined. The authors argue that neurological complications may become apparent only after the block is complete, even when patients report no warning symptoms during needle placement, which means vigilance cannot end when the needle comes out. They recommend continuous needle-tip visualization, careful puncture route selection, avoidance of excessive depth, conservative injection volumes, and consideration of alternative approaches such as the anterolateral cervical technique, which may reduce nerve root exposure in selected cases.

For patients considering SGB for insomnia, the message is not that the procedure should be abandoned, but that informed consent should include an honest discussion of neurological risk, however uncommon. New radiating pain, focal weakness, sensory loss, or reflex asymmetry after any such block should trigger immediate neurological examination, appropriate imaging, and electrophysiological testing. As a single case report, the findings cannot be generalized — anatomical variation, comorbidities, and injection characteristics all influence individual risk. But the case stands as a vivid reminder that even ultrasound-guided procedures performed by experienced hands under ideal imaging conditions can produce serious complications, and that the expanding off-label use of regional anesthesia techniques demands the same rigorous safety standards, standardized training, and post-procedural monitoring applied in their original clinical homes.

Subject of Research: Suspected C5 nerve root injury temporally associated with stellate ganglion block for refractory insomnia

Article Title: Suspected C5 Nerve Root Injury Temporally Associated With Stellate Ganglion Block for Refractory Insomnia: A Case Report

Article References: Ji, X., Niu, Z., & Wang, Y. (2026). Suspected C5 Nerve Root Injury Temporally Associated With Stellate Ganglion Block for Refractory Insomnia: A Case Report. Clinical Case Reports, 14(10), Article e73603. https://doi.org/10.1002/ccr3.73603

Image Credits: AI Generated

DOI: 10.1002/ccr3.73603

Keywords: stellate ganglion block, C5 nerve root injury, refractory insomnia, ultrasound-guided injection, electromyography, regional anesthesia, neurological complications, ropivacaine, brachial plexus, patient safety, case report, autonomic nervous system

The research team, led by Cristian D. Guerrero-Mendez and colleagues at the University of Campinas in Brazil, searched seven scientific databases from their inception through November 2025, following PRISMA reporting guidelines and registering the review protocol in advance on PROSPERO. They sorted the eligible trials into four distinct categories of electromyography-based intervention: EMG-triggered electrical stimulation, in which a patient’s own muscle activity fires electrical pulses to the target muscle once an activation threshold is crossed; that same stimulation combined with other therapies such as mirror therapy, task-oriented training, or motor imagery; EMG-controlled robotic platforms that estimate motor intention to drive assistive devices; and EMG biofeedback, which converts muscle activity into real-time visual or auditory signals. Each category was then compared against conventional, non-EMG rehabilitation across outcomes organized by the World Health Organization’s International Classification of Functioning, Disability and Health framework.

The headline finding is a striking asymmetry. EMG-triggered electrical stimulation used in isolation showed no advantage whatsoever over conventional therapy. On the Fugl-Meyer Assessment for the upper extremity, one of the gold-standard measures of post-stroke motor recovery, control groups actually fared slightly better immediately after treatment, with a small standardized mean difference of −0.53 favoring conventional care. On the Action Research Arm Test, which measures real-world arm function, the two approaches were statistically indistinguishable at every time point examined, from the end of treatment out to follow-ups of three months or longer. For a technology that has been promoted for decades as a way to reawaken paralyzed muscles by linking voluntary effort to immediate stimulation, the message is blunt: the trigger alone is not the therapy.

But when EMG-triggered stimulation was woven into a broader rehabilitation program, the picture transformed dramatically. Combined interventions produced large improvements in upper-limb motor function, with a standardized mean difference of 1.53 on the Fugl-Meyer scale, and moderate-to-large gains in grip strength, wrist flexion strength, wrist range of motion in both flexion and extension, manual dexterity on the Box and Blocks Test, and the Manual Function Test. Crucially, the benefits extended beyond raw impairment measures into the domains that matter most to patients: combined therapy improved scores on the Barthel Index of daily living independence and on both subscales of the Motor Activity Log, a patient-reported measure of how much and how well the affected arm is actually used in everyday life. In the language of the ICF framework, the combined approach produced improvements across body functions and structures, activity, participation, and patient-reported outcomes simultaneously.

The robotic arm of the evidence told a different and equally instructive story. EMG-based robotic platforms, which read a patient’s motor intention from surface muscle signals and translate it into smooth, assisted movement of the wrist or fingers, did not outperform conventional therapy on broad functional measures such as the Fugl-Meyer Assessment or the Action Research Arm Test. Yet they excelled at one specific and clinically stubborn problem: spasticity, the pathological muscle stiffness that afflicts many stroke survivors. Robotic interventions produced large reductions in finger and wrist spasticity on the Modified Ashworth Scale immediately after treatment, and remarkably, the wrist benefits persisted at long-term follow-up of three months or more, with an effect size of −2.32. The authors suggest this is because EMG-driven robotic assistance encourages active patient engagement during movement intention and execution, reinforcing the sensorimotor coupling thought to underlie neural plasticity.

EMG biofeedback, the fourth category, remains the most uncertain. Only a handful of eligible trials existed, permitting just two meta-analyses, both conducted immediately after intervention. The available evidence pointed to large improvements in wrist extension range of motion and moderate gains in Brunnstrom staging, a measure of motor recovery stage, but the certainty of this evidence was rated as very low to low under the GRADE framework. Notably, none of the included studies exploited modern biofeedback applications such as serious games, exoskeleton control, or neurofeedback-based motor learning, relying instead on classic auditory or visual feedback. The authors argue this represents an untapped frontier rather than a dead end.

Why does combining EMG-triggered stimulation with other therapies work so much better than stimulation alone? The review offers a mechanistic explanation grounded in motor learning theory. Isolated muscle activation, the authors note, does not satisfy current stroke rehabilitation guidelines, which emphasize intensive, repetitive, task-oriented practice. EMG-triggered stimulation can amplify patient involvement by rewarding voluntary effort with immediate sensory feedback, but that activation must then be channeled into functional movement patterns. When paired with mirror therapy, motor imagery, or task-specific training, the stimulation provides the neuromuscular spark while the complementary therapy directs it toward meaningful motor goals, addressing voluntary control, coordination, sensorimotor integration, and daily-living function in a single integrated program.

The review is equally candid about the field’s weaknesses. Using the Cochrane Risk of Bias 2 tool, the team judged only eight of the 38 studies to be at low risk of bias, while 13 raised some concerns and 17, nearly half, were rated high risk. Intervention protocols varied wildly, from as few as 4 sessions to as many as 126, and from 2 to 21 sessions per week, making it difficult to isolate the effect of the EMG component itself, since in some trials only the experimental group received the additional therapy. The authors also highlight practical and technical constraints: patients with severe paresis may generate no detectable muscle signal at all, rendering EMG triggering impossible, while chronic patients may produce compensatory rather than task-specific activation. Electrode displacement, crosstalk from neighboring muscles, and low signal-to-noise ratios further degrade reliability, and the skin preparation and calibration these systems demand add to therapist workload.

The authors’ evidence gap map, a visual grid of intervention types against clinical outcomes, reveals where the field stands and where it stumbles. Evidence clusters heavily around immediate post-intervention assessments, while medium- and long-term follow-up data remain scarce, and large swaths of the map are simply blank. Looking forward, the team calls for adequately powered, multicenter randomized trials with rigorous randomization and standardized outcome measures, and points to high-density EMG, which offers far greater spatial resolution and was used in none of the included studies, as a promising next-generation interface. For now, the practical prescription is clear: EMG-based interfaces should be treated as complementary tools within comprehensive rehabilitation programs, not stand-alone replacements. The muscle signal is a messenger, the review suggests, not a medicine, and it heals best when embedded in the rich context of conventional, task-oriented therapy.

Subject of Research: Effectiveness of electromyography-based interfaces for hand and wrist motor rehabilitation after stroke

Article Title: Impact of EMG-based interfaces for hand motor rehabilitation in stroke: A systematic review with evidence gap map and meta-analysis

Article References: Guerrero-Mendez, C. D., Batista, N. P., Alves Filho, J. O., Germer, C. M., & Elias, L. A. (2026). Impact of EMG-based interfaces for hand motor rehabilitation in stroke: A systematic review with evidence gap map and meta-analysis. Medical & Biological Engineering & Computing. https://doi.org/10.1007/s11517-026-03660-7

Image Credits: AI Generated

DOI: 10.1007/s11517-026-03660-7

Keywords: stroke rehabilitation, electromyography, EMG-triggered electrical stimulation, biofeedback, rehabilitation robotics, spasticity, meta-analysis, systematic review, hand function, motor recovery, ICF framework, neurorehabilitation

The research, published in Physiological Reports, was motivated by a clear problem in aging biology. As people get older, their neuromuscular system changes in ways that erode both strength and endurance. Muscle mass declines, type II fast-twitch fibers are lost in disproportionate numbers, calcium handling within muscle fibers becomes less efficient, motor unit firing rates slow, and the microvascular networks that deliver oxygen and clear metabolic waste deteriorate. Together, these changes mean older adults fatigue more quickly during repetitive tasks, which translates into real-world consequences: shorter walking endurance, poorer balance, reduced physical activity, and an elevated risk of falls and loss of independence.

Because so many of these age-related impairments are temperature-dependent, the researchers reasoned that selectively warming the quadriceps might offset some of the damage. Heating muscle above resting temperatures accelerates cross-bridge cycling, the molecular process by which myosin heads pull on actin filaments to generate force. It also speeds the release and reuptake of calcium by the sarcoplasmic reticulum, improves nerve conduction velocity, and boosts local blood flow and perfusion. Improved perfusion matters because fatigue during repeated maximal contractions is driven substantially by the accumulation of metabolic byproducts such as inorganic phosphate and hydrogen ions, which interfere with force production. If heating enhances oxygen delivery and metabolite clearance, perhaps it could delay the onset of fatigue in aged muscle, which is precisely where perfusion is most compromised.

To test this, the team recruited fifteen healthy older adults, eight of them women, with an average age of 68, all free of known illness, neuromuscular disorders, or heat intolerance. Each participant visited the laboratory once, having abstained from heavy exercise, caffeine, supplements, and alcohol for 24 hours. One thigh was wrapped in a custom garment that circulated water at 50 degrees Celsius, combined with a survival blanket, for a full 90 minutes. The contralateral limb served as a thermoneutral control. Crucially, the intervention was localized: by heating only the thigh, the researchers avoided raising core body temperature, which is known to impair performance by reducing central drive from the nervous system, a confound that may have obscured benefits in earlier whole-body heating studies.

The heating protocol worked exactly as intended. Skin temperature over the vastus lateralis rose from about 30.5 to 39.3 degrees Celsius in the heated limb, while intramuscular measurements in a small subset of volunteers showed muscle temperature climbing roughly five degrees, from about 32.2 to 37.2 degrees Celsius. Tympanic temperature and heart rate remained unchanged, confirming that the heating stayed local, and mean arterial pressure actually fell slightly. Surface electromyography of the vastus lateralis, recorded during the exercise tests, showed no significant changes in neural drive, indicating that the intervention neither boosted nor blunted the nervous system’s output to the working muscle.

The muscle function test was a demanding one. Participants completed 30 maximal knee extensions on an isokinetic dynamometer at 180 degrees per second, kicking as hard and as fast as possible through a 75-to-175-degree range of motion, both before and after the heating period. Peak torque, averaged torque across the first, middle, and final thirds of the 30 repetitions, and total work done were all analyzed. As hypothesized, the task was genuinely fatiguing: average torque fell from about 68 newton-meters in the first ten repetitions to 57 in the middle third and 51 in the final third.

Heating delivered a clear win on the single strongest contraction. Peak torque in the heated limb rose by about 8 percent after 90 minutes of warming, an increase of roughly 10 newton-meters compared with the control limb, a statistically significant difference. The control limb showed no meaningful gain. This result aligns with a growing body of evidence that passive limb heating acutely enhances peak force production, maximal power output, and even six-minute walk distance in some populations, likely through faster cross-bridge kinetics and improved calcium handling at the level of the muscle fiber.

But the hoped-for protection against fatigue never materialized. Total work done across the 30 repetitions increased by about 7 percent in the heated limb, but this change was not statistically significant, especially against a 4 percent decline in the control limb that fell within the study’s variability. There was no interaction between heating and the decline in torque across the repetition blocks, meaning the heated muscle fatigued at essentially the same rate as the unheated one. The finding echoes a 2008 study in young adults that used whole-body heating and likewise found no improvement in dynamic fatigue resistance despite higher peak forces, suggesting that whether heat is applied locally or across the whole body, it simply does not alter how quickly force output decays during repeated maximal efforts.

Why does warmth strengthen the muscle yet fail to preserve it under fatigue? The authors point to the mechanics of maximal contraction. During near-maximal efforts, the intense pressure generated inside the working muscle can effectively occlude its own blood supply, meaning any improvement in perfusion from heating cannot be exploited precisely when it would matter most. The benefits of enhanced blood flow may also unfold over longer timescales than a burst of 30 repetitions lasting less than a minute. Meanwhile, if heating does facilitate calcium cycling within the fiber, that advantage appears either too small or too easily overwhelmed by metabolic disruption to change the fatigue trajectory. The electromyography data hinted at a modest decline in neural drive as the task progressed, consistent with some contribution from central fatigue, but heating did not modulate that pattern either.

The study had limitations worth noting. A parallel exercise protocol ran between the two fatigue tests, altering muscle temperature and metabolic state, particularly in the control limb, and the control test was always performed second, raising the possibility of residual fatigue. Intramuscular temperature was measured in only three participants, and surface EMG provided only a coarse view of activation. Yet the broader message is robust and practically important: the ergogenic effects of passive heating appear to be task-specific. Prior work from the same group and others shows benefits for early force production, peak torque, and, in clinical populations with conditions like peripheral artery disease, submaximal endurance tasks such as walking. What localized heating does not do, at least in healthy older adults, is rescue performance during short, all-out, repetitive maximal efforts. For aging populations, that suggests passive heating may be best positioned as a tool to prime muscle before everyday submaximal activities, rather than a shield against high-intensity fatigue, and future research should explore whether clinical groups with impaired perfusion stand to gain more, particularly for sustained tasks where improved blood flow can actually be recruited.

Subject of Research: Effects of localized passive thigh heating on neuromuscular fatigue resistance and peak torque in older adults

Article Title: Passive thigh heating increases peak torque but does not attenuate declines in force production during repeated isokinetic knee extensor exercise in older adults

Article References: Denny, D., Low, D. C., & Gibson, O. R. (2026). Passive thigh heating increases peak torque but does not attenuate declines in force production during repeated isokinetic knee extensor exercise in older adults. Physiological Reports, 14(18), Article e71105. https://doi.org/10.14814/phy2.71105

Image Credits: AI Generated

DOI: 10.14814/phy2.71105

Keywords: passive heating, muscle fatigue, older adults, peak torque, isokinetic exercise, knee extensors, sarcoplasmic reticulum, perfusion, neuromuscular function, electromyography, aging, ergogenic aid

The case, published in the journal Cancer Reports, documents how progressive proximal muscle weakness and markedly elevated creatine phosphokinase (CPK) preceded any recognizable sign of lymphoma. On examination, the patient demonstrated symmetric weakness of the shoulder and hip girdle muscles, scoring 3 out of 5 on the Medical Research Council strength scale—able to move against gravity but not against resistance. Deep tendon reflexes were reduced, but cranial nerves, sensation, and sphincter function were intact, pointing clinicians toward a primary disease of muscle rather than nerve.

Laboratory workup sharpened the puzzle. Serum CPK, an enzyme released when muscle fibers break down, measured 900 IU/L against a reference ceiling of roughly 195 IU/L. Lactate dehydrogenase and inflammatory markers were also elevated, while a mild anemia hinted at systemic illness. Crucially, the team systematically excluded the usual suspects: antinuclear antibody, myositis-specific antibodies including anti-Jo-1, anti-Mi-2, anti-SRP, and anti-HMGCR were all negative, thyroid function and thyroid autoantibodies were normal, and testing for HIV, hepatitis B, and hepatitis C was negative. Epstein-Barr virus serology showed only evidence of past infection. No autoimmune, endocrine, toxic, or infectious explanation for the muscle injury survived scrutiny.

Electrophysiology added decisive detail. Electromyography recorded short-duration, low-amplitude motor unit potentials with early recruitment in the deltoid, first dorsal interosseous, and tensor fascia lata muscles, accompanied by prominent fibrillation potentials and positive sharp waves—a pattern characteristic of inflammatory or necrotizing myopathy. Nerve conduction studies were essentially normal, with only mild secondary axonal features, confirming that the problem lay in muscle itself rather than in the peripheral nerves supplying it. By this point, the differential diagnosis had narrowed to inflammatory myopathy, paraneoplastic myopathy, and metabolic muscle disease.

The turning point came from imaging. A contrast-enhanced computed tomography scan, obtained during the systemic evaluation, revealed enlarged left axillary lymph nodes measuring 3.5 by 2.4 centimeters along with an enlarged spleen, without focal lesions in the liver or spleen and without mass lesions elsewhere. These findings suggested a systemic lymphoproliferative process and prompted an excisional biopsy of the axillary node in April 2023. Histopathology showed complete effacement of the node’s architecture by a monomorphic population of medium-sized atypical lymphoid cells, studded with mitotic figures and interspersed tingible-body macrophages that produced the classic ‘starry-sky’ pattern—the histological signature of Burkitt lymphoma.

Immunohistochemistry sealed the diagnosis. The malignant cells expressed CD20, CD10, and BCL6, markers of a germinal-center B-cell origin, and the Ki-67 proliferation index approached 100 percent, reflecting the tumor’s hallmark near-maximal division rate. Cytogenetic analysis demonstrated rearrangement of the MYC oncogene, the molecular engine of Burkitt lymphoma. Staging studies—including bone marrow aspiration and biopsy, magnetic resonance imaging of the brain and entire spine, and cerebrospinal fluid cytology—found no marrow or central nervous system involvement, and the patient was classified as having Ann Arbor Stage III disease based on nodal involvement and splenomegaly.

One diagnostic step was deliberately sacrificed to time. Although muscle biopsy is generally considered the gold standard for classifying inflammatory myopathies, the team deferred the procedure because Burkitt lymphoma is among the most rapidly proliferative of all human malignancies, with tumor doubling times measured in days, and any delay in chemotherapy could prove catastrophic. Corticosteroids, notably, had not been given before the onset of weakness or the initial electrodiagnostic studies, ruling out the common confounder of steroid-induced myopathy; they entered the picture only afterward as part of treatment. The diagnosis of probable paraneoplastic myopathy therefore rested on the convergence of clinical findings, electrophysiology, exclusion of alternatives, and—most persuasively—what happened next.

What happened next was a striking, temporally coupled recovery. The patient began intensive therapy with the Hyper-CVAD regimen, alternating courses of cyclophosphamide, vincristine, doxorubicin, and dexamethasone with high-dose methotrexate and cytarabine, combined with rituximab targeting the CD20 antigen and standard central nervous system prophylaxis. After just the first cycle, by May 2023, his muscle strength had improved markedly and serum CPK had fallen from 900 to approximately 400 IU/L. By August 2023, upon completion of the full treatment course, CPK had normalized to 150 IU/L. Follow-up electromyography in September 2023 showed complete resolution of the previously documented myopathic abnormalities—normalized spontaneous activity, motor unit morphology, and recruitment patterns—confirmed by independent review by an experienced neurologist. At his most recent follow-up in March 2026, the patient remained asymptomatic with normal strength and no recurrence of muscle symptoms.

The clinical lesson embedded in this case concerns the phenomenon of paraneoplastic neuromuscular syndromes, in which the immune system’s response to an occult tumor spills over into attack on healthy tissue. Paraneoplastic myopathies are well described alongside solid tumors and certain hematologic malignancies, particularly Hodgkin lymphoma and intravascular large B-cell lymphoma, but their appearance ahead of sporadic Burkitt lymphoma in an immunocompetent adult appears to be exceptionally rare. Proposed mechanisms include cytokine-driven inflammation, molecular mimicry between tumor antigens and skeletal muscle proteins, and broader immune dysregulation orchestrated by the malignancy. These processes can injure muscle before any constitutional symptom, mass effect, or abnormal blood count announces the cancer, making early diagnosis genuinely difficult.

The case also distinguishes itself from prior reports of Burkitt lymphoma touching the nervous system. Earlier publications described paraplegia from spinal epidural disease, Guillain-Barré syndrome, bilateral numb chin syndrome, and oculomotor nerve palsy—all reflecting direct tumor infiltration or cranial and meningeal involvement. This patient, by contrast, had no cranial neuropathy, no sensory deficit, no cerebrospinal fluid malignant cells, and no marrow disease; electromyography pointed squarely at muscle. The neuromuscular symptoms were not a complication of advanced lymphoma but the principal reason he sought care at all. The authors acknowledge the limitations inherent in a single case report without histological confirmation of muscle involvement and with a restricted immunohistochemical panel, but argue that the full constellation of evidence strongly favors an indirect immune-mediated process tied to the lymphoma.

For clinicians, the message is pragmatic: unexplained proximal muscle weakness with elevated CPK should not be reflexively attributed to primary inflammatory myopathy when conventional investigations come back unrevealing. A careful systemic evaluation, including assessment for occult malignancy, may be warranted in atypical cases—and time matters, because Burkitt lymphoma, while ferociously aggressive, is also among the most chemosensitive cancers known. Early recognition of rare paraneoplastic presentations may mean the difference between timely, curative therapy and a fatal delay. In this instance, treating the cancer cured the muscle disease, a sequence that underscores both the diagnostic value of listening carefully to unusual symptoms and the intricate, sometimes treacherous dialogue between tumors and the immune system.

Subject of Research: Paraneoplastic myopathy as the initial presentation of sporadic Burkitt lymphoma in an immunocompetent adult

Article Title: Paraneoplastic Myopathy as a Possible Initial Presentation of Sporadic Burkitt Lymphoma in an Immunocompetent Adult: A Case Report

Article References: Khalafi‐Nezhad, A., Firouzabadi, D., mohammadkarimi, V., & Dehghanian, A. (2026). Paraneoplastic Myopathy as a Possible Initial Presentation of Sporadic Burkitt Lymphoma in an Immunocompetent Adult: A Case Report. Cancer Reports, 9(9), Article e70669. https://doi.org/10.1002/cnr2.70669

Image Credits: AI Generated

DOI: 10.1002/cnr2.70669

Keywords: Burkitt lymphoma, paraneoplastic myopathy, creatine phosphokinase, electromyography, Hyper-CVAD, MYC rearrangement, non-Hodgkin lymphoma, muscle weakness, case report, immune-mediated myopathy, oncology, neuromuscular disease